Interim Report January - March 2008 • Group income from sales of goods and royalties amounted to 289 (300) MSEK. • Operating income amounted to 10 (56) MSEK. • Revenues within the Esthetics product area amounted to 233 (240) MSEK and operating income was 55 (88) MSEK. • Net income after tax amounted to 10 (42) MSEK. • Earnings per share amounted to 0.10 (0.42) SEK. • As from April 1, 2008 all North American insurance companies reinsure endoscopic treatment of VUR (Deflux®). Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets and sells primarily medical implants. The majority of the products are based on the company's patented technology, NASHA™, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: Restylane® for filling lines and folds, contouring and creating volume in the face, Macrolane™ for body shaping, Durolane™ for the treatment of osteoarthritis of the hip and knee joints, Deflux™ for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and Solesta™ for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.
Interim Report January - March 2008
| Source: Q-Med AB